India, April 15 -- The U.S. Department of State announced the expansion of its partnership with Gilead Sciences and The Global Fund to increase access to lenacapavir (LEN), a breakthrough HIV prevention medication.
LEN is a twice-yearly injectable medication, which has shown 99.9 percent effectiveness at preventing HIV in large-scale clinical trials. Expanding upon its initial market shaping investment in access to LEN, the State Department said it is now growing its commitment to reach an additional 1 million people in high-burden countries with the two-dose annual regimen. Following the announcement, the United States and The Global Fund are committed to reach three million people in high-burden countries with LEN by 2028.
For comments ...